RBC keeps USD 9.00 target for Bausch Health stock
Published on 10/20/2026 at 19:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- RBC set a USD 9.00 target on October 8, 2026, 38.46 percent above the NYSE price.
- OKEDI reimbursement expanded to seven Canadian provinces on October 19, 2026.
- Bausch Health stock costs EUR 5.78 at Lang & Schwarz on October 20, 2026 at 6:57 p.m. CEST, 1.23 percent above the Tradegate close of October 16, 2026.
- Bausch Health will report third-quarter 2026 results on October 28, 2026.
On October 8, 2026, Royal Bank of Canada reissued a sector perform rating and set a USD 9.00 price target for Bausch Health, MarketBeat reports. The target was 38.46 percent above the NYSE price of USD 6.50, while the euro quote stood at EUR 5.78 at Lang & Schwarz on October 20, 2026 at 6:57 p.m. CEST, up 1.23 percent versus the Tradegate close of October 16, 2026 (EUR 5.71).
Seven provinces expand access
Bausch Health Canada announced on October 19, 2026, that public reimbursement for OKEDI, an extended-release risperidone injection, had expanded to seven provinces. Coverage also reached several federal drug plans, including programs for veterans and military personnel, according to the company's Bausch Health release. The treatment is available in 75 milligram and 100 milligram formulations for adults with schizophrenia.
Stock stays inside its yearly range
The NYSE quote was USD 6.50 on October 20, 2026 at 1:01 p.m. ET. Its 52-week range was USD 4.33 to USD 8.00, placing the price 18.75 percent below the high and 50.12 percent above the low. The quote was up 2.85 percent year to date, with 804,267 shares traded at the recorded time.
What does the USD 9.00 target imply?
The analyst target sits above the current NYSE price, but Bausch Health's latest reported quarter also provides a measurable operating reference. For the second quarter of 2026, revenue reached USD 2.83 billion and earnings per share were USD 1.26 against a USD 0.96 consensus estimate, according to MarketBeat. The company also generated USD 670.00 million in operating cash flow during that quarter.
Bausch Health's market capitalization was USD 2.4 billion on October 20, 2026. The next scheduled company date is October 28, 2026, when Bausch Health will release third-quarter results after the market close and hold its call at 5:00 p.m. EDT, as stated in its company release.
Price and reporting date
The analyst target, reimbursement expansion and October 28 reporting date give investors three dated reference points. The euro quote was trading in after-hours at EUR 5.78 at Lang & Schwarz on October 20, 2026 at 6:57 p.m. CEST, up 1.23 percent versus the Tradegate close of October 16, 2026 (EUR 5.71).
The further course of trading is shown by the continuously updated real-time quote of Bausch Health stock.
Bausch Health stock at a glance
- Company: Bausch Health Companies Inc.
- ISIN: CA0717341071
- WKN: A2JQ1X
- Ticker: BHC
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 20, 2026, 6:57 p.m. CEST): EUR 5.78
- Change versus Tradegate close: plus 1.23 percent
- Tradegate close (October 16, 2026): EUR 5.71
- Market capitalization: USD 2.4 billion (as of October 20, 2026)
- 52-week range: USD 4.33-8.00 (as of October 20, 2026)
- Sector / Industry: Healthcare / specialty and generic pharmaceuticals
Market context: Market report S&P/TSX Composite.
